TP53 and B-cell chronic lymphocytic leukemia: Given the increasing evidence of the importance of the hypoxia pathway in CLL pathogenesis and its potential druggability [54, 55], our results point to the possibility of hypoxia pathway targeting even in wt‐TP53 patients.